This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Sloan-Kettering Institute for Cancer Research provides $263,086 to develop a multiparametric endoscopic ultrasound (MPEUS) imaging system and methodology for improved pancreatic cancer screening and characterization. The goal is to create a non-subjective, quantitative approach for detecting and characterizing pancreatic cancer and precursor lesions in high-risk...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $677,176 to The Research Foundation For The State University Of New York (RF SUNY) to advance the development of interstitial chemophototherapy (I-CPT) as a novel treatment approach for locally advanced pancreatic cancer (PACA). The key products and services to be delivered under this 4-year award include: Defining optimal I-CPT light dosimetry for treating large PACA tumors...
This Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) aims to advance a local controlled release platform for intratumoral delivery of hyaluronidase to improve the efficacy of systemically administered drugs for pancreatic ductal adenocarcinomas (PDAC). The award totals $599,474 and will fund a 5-year project from Sep 1, 2024 to Aug 31, 2029. The key products and services to be delivered through this grant include: 1) using...
The National Cancer Institute (NCI) awarded Oncotab, Inc. a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop an optimized targeted radiotherapy for pancreatic ductal adenocarcinoma (PDAC). Oncotab, Inc. will conduct a structured design of experiments to evaluate the use of a humanized tumor-associated MUC1 (TMUC1) antibody, as well as a tandem single-chain variable fragment (scFv) construct, labeled with alpha and beta particle-emitting radioisotopes....
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $585,458 to Baylor College of Medicine to further validate and refine a mass spectrometry-based proteomic assay for early detection of pancreatic ductal adenocarcinoma (PDAC). The project aims to: 1) determine the performance characteristics and robustness of the assay for clinical utilization; 2) refine the assay's accuracy and thresholds for PDAC detection...
The National Cancer Institute (NCI) awarded a $1,271,498 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center (UNMC) Division. The goal of this 5-year award, effective December 19, 2024, is to develop a porcine model of pancreatic cancer that can be used to more efficiently test experimental therapies and medical devices for pancreatic cancer management. Specifically, the...
This federal Cooperative Agreement award, funded by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to create a comprehensive 3D atlas depicting the progression of pancreatic cancer precursor lesions to invasive pancreatic ductal adenocarcinoma (PDAC) in individuals with genetic defects in DNA repair genes (BRCA1, BRCA2, PALB2). The $1,035,138 award, with a period of performance from Sep 1, 2024 to Aug 31, 2029, will support...
The National Cancer Institute (NCI) awarded a $1,199,514 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Mayo Clinic Arizona to develop a comprehensive, fair, and scalable multimodal AI model called PRECISE that combines imaging and non-imaging data to enable early detection of pancreatic cancer. Key aims include: 1) developing deep learning models to segment imaging biomarkers from abdominal CT scans, 2) creating a fusion model using a graph neural...
This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived...
This $1,377,000 Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) aims to develop a novel oncolytic virus platform called VMG for the treatment of pancreatic ductal adenocarcinoma (PDAC). The key products and services to be delivered under this 3-year project include: Evaluating the VMG oncolytic virus vector's ability to selectively target and destroy PDAC tumor cells while sparing normal tissues, through expression of enzymes to break...